Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H13Cl2NO4 |
Molecular Weight | 354.185 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1
InChI
InChIKey=MNIPYSSQXLZQLJ-UHFFFAOYSA-N
InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
DescriptionSources: http://www.drugs.com/pro/clanza-cr.html
Sources: http://www.drugs.com/pro/clanza-cr.html
Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) analog of Diclofenac. It is used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The dose is 100 mg twice daily, and should not be given to people with porphyria or breastfeeding mothers and is not recommended for children. Aceclofenac is a cytokine inhibitor. Aceclofenac works by blocking the action of a substance in the body called cyclo-oxygenase. Cyclo-oxygenase is involved in the production of prostaglandins (chemicals in the body which cause pain, swelling and inflammation). Aceclofenac is the glycolic acid ester of diclofenac. The incidence of gastric ulcerogenicity of aceclofenac has been reported to be significantly lower than that of other frequently prescribed NSAIDs: for instance, 2-fold less than naproxen, 4-fold less than diclofenac, and 7-fold less than indomethacin. Aceclofenac is metabolized in human hepatocytes and human microsomes to form [2-(2',6'-dichloro-4'-hydroxy- phenylamino)phenyl] acetoxyacetic acid as the major metabolite, which is then further conjugated.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18547825 |
3.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date2011 |
|||
Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date2011 |
|||
Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date2011 |
|||
Palliative | Clanza CR Approved UseCLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. Launch Date2011 |
PubMed
Title | Date | PubMed |
---|---|---|
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. | 2001 |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers. | 2001 Feb |
|
In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs). | 2001 May |
|
Photoallergic contact dermatitis from aceclofenac. | 2001 Sep |
|
Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. | 2002 Oct 11 |
|
Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. | 2003 |
|
Stability indicating methods for the determination of aceclofenac. | 2003 Feb |
|
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. | 2004 |
|
Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. | 2004 Apr |
|
Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. | 2005 Jul 1 |
|
Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. | 2005 Nov 10 |
|
Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. | 2007 Aug |
|
Simultaneous determination of aceclofenac, paracetamol, and chlorzoxazone by RP-HPLC in pharmaceutical dosage form. | 2008 Aug |
|
Mathematical evaluation of similarity factor using various weighing approaches on aceclofenac marketed formulations by model-independent method. | 2008 Jan |
|
Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. | 2008 Jul 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8730134
In vitro adhesion assays were developed to examine the effects of aceclofenac on both neutrophil adhesion to tumor necrosis factor alpha stimulated human umbilical vein endothelial cells under nonstatic conditions, and homotypic neutrophil aggregation induced by anti-ICAM-3 and anti-CD18 monoclonal antibodies (Mab)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM02AA25
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
WHO-ATC |
M02AA25
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
WHO-VATC |
QM01AB16
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
WHO-ATC |
M01AB16
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C80534
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
m1293
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
RPK779R03H
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
100000092759
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
71771
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
16689
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | RxNorm | ||
|
43
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
ACECLOFENAC
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
5608
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
RPK779R03H
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL93645
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
89796-99-6
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
SUB05200MIG
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
DTXSID7045522
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
C056498
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
31159
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY | |||
|
DB06736
Created by
admin on Fri Dec 15 15:47:37 GMT 2023 , Edited by admin on Fri Dec 15 15:47:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY